Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Status: | Recruiting |
---|---|
Conditions: | Lung Cancer, Lung Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/13/2019 |
Start Date: | April 7, 2017 |
End Date: | April 2022 |
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or
without local consolidation therapy works in treating patients with stage IV non-small cell
lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium,
erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Local consolidation therapy such as radiation/stereotactic body radiation or
surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy
and local consolidation therapy together may work better than maintenance chemotherapy alone
in treating patients with stage IV non-small cell lung cancer.
without local consolidation therapy works in treating patients with stage IV non-small cell
lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium,
erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Local consolidation therapy such as radiation/stereotactic body radiation or
surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy
and local consolidation therapy together may work better than maintenance chemotherapy alone
in treating patients with stage IV non-small cell lung cancer.
PRIMARY OBJECTIVES:
Phase II
To evaluate the impact of adding local consolidative therapy (LCT) to maintenance systemic
therapy versus maintenance systemic therapy alone on progression-free survival for patients
with metastatic non-small cell lung cancer (NSCLC) with no evidence of progression and
limited metastatic sites after first-line systemic therapy.
Phase III
To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance
systemic therapy alone on overall survival for patients with metastatic NSCLC with no
evidence of progression and limited metastatic sites after first-line systemic therapy.
SECONDARY OBJECTIVES:
I. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance
systemic therapy alone on in-field local failure.
II. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance
systemic therapy alone on the time to development of new lesions.
III. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance
systemic therapy alone on toxicity.
IV. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance
systemic therapy alone on duration of maintenance systemic therapy usage.
V. To evaluate the effect of adding LCT to systemic therapy in limited stage IV NSCLC on
Quality of Life (QOL) VI. To collect biospecimens and evaluate the correlation between
clinical outcomes and circulating tumor DNA (ctDNA).
OUTLINE: Patients are randomized into 1 of 2 arms.
ARM 1 (CHEMOTHERAPY ALONE): ): Patients may receive docetaxel intravenously (IV) over 60
minutes on Day 1, erlotinib hydrochloride orally (PO) once daily (QD), or gemcitabine IV over
30 minutes on Days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive
pemetrexed disodium IV over 10 minutes on Day 1 alone or in combination with pembrolizumab IV
over 30 minutes. Courses repeat every 21 days in the absence of disease progression or
unacceptable toxicity.
ARM 2 (SBRT AND CHEMOTHERAPY): Patients undergo LCT over 2-4 weeks. If LCT cannot be used to
treat primary disease sites, patients also undergo intensity-modulated radiation therapy
(IMRT) or 3-dimensional conformal radiation therapy (3DCRT) over 3-5 weeks. Within 2 weeks
after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients
may possibly undergo surgery.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, then annually thereafter.
Phase II
To evaluate the impact of adding local consolidative therapy (LCT) to maintenance systemic
therapy versus maintenance systemic therapy alone on progression-free survival for patients
with metastatic non-small cell lung cancer (NSCLC) with no evidence of progression and
limited metastatic sites after first-line systemic therapy.
Phase III
To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance
systemic therapy alone on overall survival for patients with metastatic NSCLC with no
evidence of progression and limited metastatic sites after first-line systemic therapy.
SECONDARY OBJECTIVES:
I. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance
systemic therapy alone on in-field local failure.
II. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance
systemic therapy alone on the time to development of new lesions.
III. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance
systemic therapy alone on toxicity.
IV. To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance
systemic therapy alone on duration of maintenance systemic therapy usage.
V. To evaluate the effect of adding LCT to systemic therapy in limited stage IV NSCLC on
Quality of Life (QOL) VI. To collect biospecimens and evaluate the correlation between
clinical outcomes and circulating tumor DNA (ctDNA).
OUTLINE: Patients are randomized into 1 of 2 arms.
ARM 1 (CHEMOTHERAPY ALONE): ): Patients may receive docetaxel intravenously (IV) over 60
minutes on Day 1, erlotinib hydrochloride orally (PO) once daily (QD), or gemcitabine IV over
30 minutes on Days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive
pemetrexed disodium IV over 10 minutes on Day 1 alone or in combination with pembrolizumab IV
over 30 minutes. Courses repeat every 21 days in the absence of disease progression or
unacceptable toxicity.
ARM 2 (SBRT AND CHEMOTHERAPY): Patients undergo LCT over 2-4 weeks. If LCT cannot be used to
treat primary disease sites, patients also undergo intensity-modulated radiation therapy
(IMRT) or 3-dimensional conformal radiation therapy (3DCRT) over 3-5 weeks. Within 2 weeks
after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients
may possibly undergo surgery.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, then annually thereafter.
Inclusion Criteria:
- Patients must have the psychological ability and general health that permits
completion of the study requirements and required follow up
- Women of childbearing potential and men who are sexually active should be willing and
able to use medically acceptable forms of contraception during the trial and for up to
180 days after completion of all treatment to prevent pregnancy or fathering a child.
- Pathologically proven diagnosis of NSCLC, with metastases (stage IV disease) present
prior to registration; this includes patients newly diagnosed with metastatic disease
or those initially diagnosed and treated for stage I-III NSCLC who ultimately develop
metastases
- Appropriate stage for study entry based on the following diagnostic workup:
- History/physical examination within 30 days prior to registration
- Imaging proof of limited metastatic disease and response to therapy/stable
disease, by at least CT chest through the adrenals or PET/CT within 30 days prior
to registration
- Zubrod performance status 0, 1, or 2 within 30 days prior to registration
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of
normal (ULN) or ≤ 5 × ULN with metastatic liver disease
- Total bilirubin ≤ 1.5 × ULN
- Absolute neutrophil count (ANC) ≥ 500 cells/mm^3
- Creatinine clearance ≥ 45 mL/min/1.73 m^2 for patients with creatinine levels above
institutional normal
- Platelets ≥ 50,000 cells/mm^3
- Negative serum pregnancy test within one week prior to registration for females of
childbearing potential
- Patients must have received first-line/induction chemotherapy (4 cycles) and achieved
stable disease or a partial response
- Prior systemic chemotherapy as part of concurrent treatment approach for previously
diagnosed stage III NSCLC, as adjuvant therapy for previously resected NSCLC, or for
other previous cancers is permitted
- Prior radiotherapy for patients with brain metastases prior to enrollment is
acceptable
- Patients must have measurable disease at baseline and 3 or fewer discrete,
extracranial metastatic disease sites that are technically amenable to SBRT
- For de novo stage IV NSCLC patients (patients with metastatic disease at first
presentation), primary disease must be treatable with local therapy in the form of
SBRT or hypofractionated radiation; if the primary disease is found in the peripheral
or central lung parenchyma without nodal disease for instance, SBRT may be employed;
if primary disease is more advanced with involvement of the mediastinum (T4 tumor,
N1-N3 disease, etc.), these volumes should be technically treatable with
hypofractionated radiation
- If primary disease in the thoracic cavity was previously treated with local therapy in
the form of surgery, any local/regional disease recurrence should be technically
treatable with SBRT or hypofractionated radiation after induction systemic therapy
- Patients must be registered within 35 days of administration of the last dose of
first-line/induction systemic therapy
- The patient or a legally authorized representative must provide study-specific
informed consent prior to study entry
- Patients with brain metastases are eligible if these lesions have been previously
treated and the patients have no clinical or radiographic evidence of progression
prior to enrollment
Exclusion Criteria:
- Clinical or radiologic evidence of untreated and/or progressive brain metastases
- Cutaneous metastasis of NSCLC
- Metastatic disease invading the esophagus, stomach, intestines, or mesenteric lymph
nodes if not a candidate for surgery for these lesions
- Prior invasive malignancy (except non-melanomatous skin cancer, low or intermediate
risk prostate cancer, or in situ carcinoma of breast, oral cavity, skin, or cervix)
unless disease free for a minimum of one year
- Metastases located within 3 cm of previously irradiated (< 3Gy per fraction)
structures if if not a candidate for surgery for these lesions and if:
- Spinal cord previously irradiated to > 40 Gy
- Brachial plexus previously irradiated to > 50 Gy
- Small intestine, large intestine, or stomach previously irradiated to > 45 Gy
- Brainstem previously irradiated to > 50 Gy
- Lung previously irradiated with prior V20 Gy > 35%
- Patients receiving targeted therapy (non-cytotoxic systemic therapy) for NSCLC in the
first-line setting
- If a patient has progressed in previous areas of primary disease that received
definitive doses of radiation, these patients would require re-irradiation in previous
high dose anatomic areas and are not eligible for this study
- Patients with malignant pleural effusions that do not resolve after first-line
systemic therapy; patients with pleural effusions that have become too small for
thoracentesis at the time of registration would be permitted on study, indicating a
significant response to first-line chemotherapy
- Patients with more than 3 discrete locations of extra-cranial metastatic disease after
first-line systemic therapy requiring more than 3 SBRT plans to cover these distinct
metastatic disease entities
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of
registration
- Patients who are pregnant or nursing
- Participation in any investigational drug study (excluding non-oncology and/or symptom
management studies) within 4 weeks prior to registration
- Known human immunodeficiency virus (HIV) positive with cluster of differentiation 4
(CD4) count < 200 cells/microliter; note that patients who are HIV positive are
eligible, provided they are under treatment with highly active antiretroviral therapy
(HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to
registration; note also that HIV testing is not required for eligibility for this
protocol
- Patients who received prior non-induction pembrolizumab, patients on chronic steroids
or who have active autoimmune disease for which they received systemic treatment in
the previous 2 years with corticosteroids, disease modifying agents, or
immunosuppressive drugs. Replacement therapy (thyroxine, insulin or physiological
corticosteroid replacement for adrenal or pituitary insufficiency) is allowed.
Patients with active interstitial lung disease or who have a history of pneumonitis
for which they had received glucocorticoids are not eligible
- Prior bevacizumab therapy
We found this trial at
182
sites
Wilmington, North Carolina 28401
Principal Investigator: Michael A. Papagikos
Phone: 910-251-1839
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Gregory N. Gan
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
Duarte, California 91010
(626) 256-4673
Principal Investigator: Sagus Sampath
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: Todd A. Swanson
Phone: 409-772-1950
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Sanjay Maraboyina
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Benjamin B. Bridges
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Yuhchyau Chen
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Ying Li
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
Akron, Ohio 44307
Principal Investigator: Mitchel L. Fromm
Phone: 866-223-8100
Click here to add this to my saved trials
4650 Jefferson Lane Northeast
Albuquerque, New Mexico 87109
Albuquerque, New Mexico 87109
Principal Investigator: Gregory N. Gan
Phone: 505-272-0530
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Gregory N. Gan
Phone: 505-272-0530
Click here to add this to my saved trials
Atlanta, Georgia 30303
Principal Investigator: Kristin A. Higgins
Phone: 404-489-9164
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Kristin A. Higgins
Phone: 404-778-1868
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Kristin A. Higgins
Phone: 412-339-5294
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Kristin A. Higgins
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Pranshu Mohindra
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Click here to add this to my saved trials
Baton Rouge, Louisiana 70805
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
4950 Essen Lane
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-757-0343
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Christopher U. Jones
Phone: 415-209-2686
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Kimberley S. Mak
Phone: 617-638-8265
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Nitin Ohri
Phone: 718-379-6866
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Nitin Ohri
Phone: 718-379-6866
Click here to add this to my saved trials
130 S Bryn Mawr Ave
Bryn Mawr, Pennsylvania 19010
Bryn Mawr, Pennsylvania 19010
(484) 337-3000
Principal Investigator: Albert S. DeNittis
Phone: 484-476-2649
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Paul J. Hesketh
Phone: 781-744-8027
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Ellen L. Ziaja
Phone: 414-302-2304
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Timothy J. Kruser
Phone: 312-695-1301
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Jordan Kharofa
Phone: 513-558-4553
Click here to add this to my saved trials
5680 Bow Pointe Drive
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Principal Investigator: Steven R. Miller
Phone: 313-576-9790
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216-368-2000
Principal Investigator: Mitchell Machtay
Phone: 800-641-2422
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Gregory M. M. Videtic
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
Cleveland, Ohio 44111
216.476.7000
Principal Investigator: Gregory M. M. Videtic
Phone: 866-223-8100
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
Click here to add this to my saved trials
Clinton Township, Michigan 48038
Principal Investigator: Eleanor M. Walker
Phone: 313-916-1784
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
Click here to add this to my saved trials
1400 East Boulder Street
Colorado Springs, Colorado 80909
Colorado Springs, Colorado 80909
Principal Investigator: Robert J. Hoyer
Phone: 719-365-2406
Click here to add this to my saved trials
Columbia, Maryland 21044
Principal Investigator: Pranshu Mohindra
Phone: 443-546-1300
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Jose G. Bazan
Phone: 800-293-5066
Click here to add this to my saved trials
3100 Plaza Properties Blvd
Columbus, Ohio 43219
Columbus, Ohio 43219
(614) 383-6000
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
The Mark H. Zangmeister Center At The Zangmeister Center, we appreciate that our patients have...
Click here to add this to my saved trials
Corvallis, Oregon 97330
Principal Investigator: Michael Wahl
Phone: 541-768-4352
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Puneeth Iyengar
Phone: 214-648-7097
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
Danville, Pennsylvania 17822
570-271-6211
Principal Investigator: Fiori Alite
Phone: 570-271-5251
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
Des Moines, Iowa 50309
(515) 241-6212
Principal Investigator: Robert J. Behrens
Phone: 515-241-6727
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Eleanor M. Walker
Phone: 313-916-1784
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
Detroit, Michigan 48201
(313) 833-1785
Principal Investigator: Steven R. Miller
Phone: 313-576-9790
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
Click here to add this to my saved trials
Dover, New Hampshire 03820
Principal Investigator: Arul Mahadevan
Phone: 603-740-2150
Click here to add this to my saved trials
Drexel Hill, Pennsylvania
Principal Investigator: Rachelle M. Lanciano
Phone: 610-284-8237
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Steven R. Bonin
Phone: 412-339-5294
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Thomas E. Stinchcombe
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
820 4th St N
Fargo, North Dakota 58102
Fargo, North Dakota 58102
(701) 234-6161
Principal Investigator: Preston D. Steen
Phone: 701-234-6161
Roger Maris Cancer Center Sanford Health is an integrated health system headquartered in the Dakotas...
Click here to add this to my saved trials
Farmington Hills, Michigan 48334
Principal Investigator: Steven R. Miller
Phone: 313-576-9790
Click here to add this to my saved trials
Flint, Michigan 48532
Principal Investigator: Steven R. Miller
Phone: 313-576-9790
Click here to add this to my saved trials
Fond Du Lac, Wisconsin 54937
Principal Investigator: Ellen L. Ziaja
Phone: 414-302-2304
Click here to add this to my saved trials
1024 S Lemay Ave
Fort Collins, Colorado 80524
Fort Collins, Colorado 80524
(970) 495-7000
Principal Investigator: Robert J. Hoyer
Phone: 970-297-6150
Poudre Valley Hospital A 270-bed regional medical center offering a wide array of treatments, surgeries,...
Click here to add this to my saved trials
2200 Randallia Drive
Fort Wayne, Indiana 46805
Fort Wayne, Indiana 46805
Principal Investigator: Brian K. Chang
Phone: 260-373-8888
Click here to add this to my saved trials
Fort Wayne, Indiana 46845
Principal Investigator: Brian K. Chang
Phone: 877-784-4673
Click here to add this to my saved trials
1600 Southwest Archer Road
Gainesville, Florida 32610
Gainesville, Florida 32610
Principal Investigator: Anamaria R. Yeung
Phone: 412-339-5294
Click here to add this to my saved trials
Germantown, Wisconsin 53022
Principal Investigator: Ellen L. Ziaja
Phone: 414-302-2304
Click here to add this to my saved trials
Gilbert, Arizona 85297
Principal Investigator: Christopher A. Biggs
Phone: 480-922-4600
Click here to add this to my saved trials
Glen Burnie, Maryland 21061
Principal Investigator: Pranshu Mohindra
Phone: 410-553-8100
Click here to add this to my saved trials
Goshen, Indiana 46526
Principal Investigator: Houman Vaghefi
Phone: 574-364-2973
Click here to add this to my saved trials
Grafton, Wisconsin 53024
Principal Investigator: Ellen L. Ziaja
Phone: 414-302-2304
Click here to add this to my saved trials
1117 29th St S
Great Falls, Montana 59405
Great Falls, Montana 59405
(406) 771-7300
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Benefis Healthcare- Sletten Cancer Institute Benefis Hospitals has 516 beds at its two campuses (that...
Click here to add this to my saved trials
2845 Greenbrier Rd
Green Bay, Wisconsin 54311
Green Bay, Wisconsin 54311
(920) 288-8000
Principal Investigator: Ellen L. Ziaja
Phone: 414-302-2304
Aurora BayCare Medical Center Aurora BayCare Medical Center is a 167-bed, full-service hospital serving the...
Click here to add this to my saved trials
835 S Van Buren St
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54301
Principal Investigator: Matthew L. Ryan
Phone: 920-433-8889
Click here to add this to my saved trials
1726 Shawano Avenue
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54303
Principal Investigator: Matthew L. Ryan
Phone: 412-339-5294
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
Greenville, South Carolina 29615
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
Greenwood, South Carolina 29646
Principal Investigator: Carolyn D. Britten
Phone: 864-725-4771
Click here to add this to my saved trials
Greer, South Carolina 29651
Principal Investigator: Patricia C. Griffin
Phone: 864-560-6104
Click here to add this to my saved trials
Greer, South Carolina 29650
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
24800 SE Stark St
Gresham, Oregon 97030
Gresham, Oregon 97030
(503) 674-1122
Principal Investigator: Andrew Y. Kee
Phone: 503-413-2150
Legacy Mount Hood Medical Center Legacy Mount Hood Medical Center, East County's full-service community hospital,...
Click here to add this to my saved trials
4300 Londonderry Road
Harrisburg, Pennsylvania 17109
Harrisburg, Pennsylvania 17109
Principal Investigator: Timothy F. Burns
Phone: 717-724-6765
Click here to add this to my saved trials
Hilton Head Island, South Carolina 29926
Principal Investigator: Howard A. Zaren
Phone: 912-819-5704
Click here to add this to my saved trials
1301 Punchbowl St
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
(808) 538-9011
Principal Investigator: Kenneth N. Sumida
Phone: 412-339-5294
Queen's Medical Center The Queen's Medical Center, located in downtown Honolulu, Hawaii, is a private,...
Click here to add this to my saved trials
Honolulu, Hawaii 96817
Principal Investigator: Kenneth N. Sumida
Phone: 808-547-6881
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Daniel Gomez
Phone: 877-312-3961
Click here to add this to my saved trials
8111 South Emerson Avenue
Indianapolis, Indiana 46237
Indianapolis, Indiana 46237
Principal Investigator: Michael S. Eaton
Phone: 317-528-7060
Click here to add this to my saved trials
1400 North Ritter Avenue
Indianapolis, Indiana 46219
Indianapolis, Indiana 46219
Principal Investigator: Daniel W. Weed
Phone: 800-777-7775
Click here to add this to my saved trials
Indianapolis, Indiana 46256
Principal Investigator: Daniel W. Weed
Phone: 317-621-7104
Click here to add this to my saved trials
Indianapolis, Indiana 46227
Principal Investigator: Daniel W. Weed
Phone: 317-497-2823
Click here to add this to my saved trials
4500 San Pablo Rd S
Jacksonville, Florida 32224
Jacksonville, Florida 32224
(904) 953-2000
Principal Investigator: Helen J. Ross
Phone: 855-776-0015
Mayo Clinic Florida Thousands of people come to Mayo Clinic in Jacksonville, Fla., annually for...
Click here to add this to my saved trials
310 Sunnyview Ln
Kalispell, Montana 59901
Kalispell, Montana 59901
(406) 752-5111
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Kalispell Regional Medical Center Nestled in the beautiful Flathead Valley of Northwestern Montana, Kalispell Regional...
Click here to add this to my saved trials
Kansas City, Kansas 66160
Principal Investigator: Fen Wang
Phone: 913-945-7552
Click here to add this to my saved trials
Kansas City, Missouri 64218
Principal Investigator: John H. Park
Phone: 800-525-1483
Click here to add this to my saved trials
Kenosha, Wisconsin 53142
Principal Investigator: Ellen L. Ziaja
Phone: 414-302-2304
Click here to add this to my saved trials
La Crosse, Wisconsin
Principal Investigator: Collin D. Driscoll
Phone: 608-775-2385
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
La Jolla, California 92093
(858) 822-6100
Principal Investigator: James J. Urbanic
Phone: 858-822-5354
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
Click here to add this to my saved trials
325 Maine Street
Lawrence, Kansas 66044
Lawrence, Kansas 66044
(785) 505-5000
Principal Investigator: Pavan S. Reddy
Phone: 316-268-5374
Lawrence Memorial Hospital Lawrence Memorial Hospital (LMH), in collaboration with its medical staff, is dedicated...
Click here to add this to my saved trials
Lewisburg, Pennsylvania 17837
Principal Investigator: Fiori Alite
Phone: 570-374-8555
Click here to add this to my saved trials
Libertyville, Illinois 60048
Principal Investigator: Dean J. Conterato
Phone: 630-929-6129
Click here to add this to my saved trials
London, Ontario
Principal Investigator: Alexander V. Louie
Phone: 519-685-8600
Click here to add this to my saved trials
1983 Marengo St
Los Angeles, California 90033
Los Angeles, California 90033
(323) 226-2622
Principal Investigator: Jason C. Ye
Phone: 323-865-0451
Los Angeles County-USC Medical Center The origins of LAC+USC Medical Center date back to 1878,...
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Jason C. Ye
Phone: 323-865-0451
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: Neal E. Dunlap
Phone: 502-562-3429
Click here to add this to my saved trials
Mansfield, Ohio 44906
Principal Investigator: Gregory M. M. Videtic
Phone: 866-223-8100
Click here to add this to my saved trials